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Background: Upper gastrointestinal bleeding is the severe complication of stress-related mucosal disease in
hospitalized patients. In intensive care units (ICU), risk factors are well deﬁned and only mechanical
ventilation and coagulopathy proved to be relevant for signiﬁcant bleeding. On the contrary, in non-ICU
settings there is no consensus about this issue. Nevertheless, omeprazole is still widely used in prophylaxis of
bleeding. The objective of our study was to evaluate the relevance of stress-related mucosal disease bleeding
in patients admitted to an internal medicine ward, and the role of omeprazole in its prophylaxis.
Methods:We conducted a retrospective study in which we analysed consecutive patients who were admitted
to our ward over a year. We recorded demographic characteristics of the patients, potential risk factors for
stress-related mucosal disease (clinical data, laboratory, and medication), administration of prophylactic
omeprazole, and total cost of this prophylaxis. Patients with active gastrointestinal bleeding on the
admission were excluded. We recorded every upper gastrointestinal bleeding event with clinical relevance.
Results: Five hundred and thirty-ﬁve patients, mean age 70 years, mean length of stay 9.6±7.7 days; 140
(26.2%) patients were treated with 40 mg of omeprazole intravenously, 193 (36.1%) with 20 mg of
omeprazole orally, and 202 (37.8%) patients had no prophylaxis. There was only one episode (0.2%) of
clinically relevant bleeding.
Conclusion: In patients admitted to an internal medicine ward, incidence of upper gastrointestinal bleeding
as a complication of stress-related mucosal disease is low. We found that there is no advantage in
prophylaxis with omeprazole.
© 2010 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.1. Introduction
Stress-related mucosal disease is deﬁned as a superﬁcial lesion
most commonly observed in the acid-producing portions of gastric
mucosa that can occur after the ﬁrst 24 h of hospitalization [1]. Its
pathogenesis has not been explained completely but it has been
suggested that hypoperfusion of the upper gastrointestinal tract might
be crucial [1]. Although stress-relatedmucosal disease can be the cause
of 15% of all the upper gastrointestinal bleeding events, actual
hæmorrhage is only measurable in 6% of cases, being clinically
signiﬁcant in less than 3% [2]. In intensive care units (ICU), predispos-
ing conditions for stress-related mucosal disease are prolonged
mechanical ventilation, coagulopathy, shock, major trauma, surgery,
or burn, and multiple organ failure [3,4]. However, randomized trials, Faculty of Medical Sciences,
30 1169-056 Lisboa, Portugal.
ral).
ration of Internal Medicine. Publishhave suggested that only the ﬁrst two entities might be relevant, as in
their absence the incidence of clinical signiﬁcant bleeding is less than
0.1% [4,5].
Despite bleeding from stress-related mucosal disease is not an
exclusive condition of the critically ill, little is known about its
incidence, cause and outcome in non-ICU patients [6]. Although
patients are admitted to general medical wards with an increasing
number of severe co-morbidities, most of the conditions described
above as high risk factors for the development of this complication are
infrequent in these patients.
Proton-pump-inhibitors (PPIs) are the most effective agents for
reducing gastric acid secretion, being frequently used in many
gastrointestinal disorders [7,8]. Nevertheless, evidence of their
beneﬁt in the prophylaxis of bleeding from stress-related mucosal
disease is lacking. Despite this, omeprazole and other PPIs are
commonly used for this purpose, either in critical care or in general
medical wards [9].
The aims of our study were to evaluate the incidence of upper
gastrointestinal bleeding possibly associated with stress-related
mucosal disease in patients admitted to an internal medicine ward,
as well as the potential role of omeprazole in its prophylaxis.ed by Elsevier B.V. All rights reserved.
387M.C. Amaral et al. / European Journal of Internal Medicine 21 (2010) 386–3882. Patients and methods
Consecutive patients hospitalized in our internal medicine depart-
ment over a year (from 1st January to 31st December) were
retrospectively analysed. Patients were ineligible if they had gastroin-
testinal bleeding (hæmatemesis, melenæ or hæmatochezia) within
48 h before or 24 h after admission. We recorded demographic data,
length of hospitalization, diagnoses, and number of potential severity
criteria [4] at the time of admission such as: moderate to severe
infection (core temperature N38.5 °C or b35 °C, and white-cell count
N15,000/mm3 or b3000/mm3); hypotension (systolic blood pressure
b80 mmHg for 2 h or more, or a decrease of ≥30 mmHg in it); renal
failure (creatinine clearance rate b40 mL per minute, b500 mL of urine
per day, or serum creatinine concentration N2.8 mg/dL), coagulopathy
(platelet count b50,000/mm3, International Normalized Ratio N1.5, or
partial-thromboplastin time N2.0 times the control value); hepatic
failure (any two of the following: serum bilirubin concentration
N8.8 mg/dL, serum aspartate aminotransferase level N500 U/L, serum
albumin b41 g/L, and clinical signs and symptoms of hepatic coma); a
Glasgowcoma score b5.We recorded the Karnofsky score of eachpatient
at admission (I—independent for daily activities, II—partially dependent,
or III—totally dependent), the administrationof glucocorticoids,warfarin,
non-fractioned or low molecular weight heparin, anti-platelet agents,
and nonsteroidal antiinﬂammatory drugs (NSAIDs) during hospitaliza-
tion, and the use of omeprazole only for prophylactic purposes. The
treatment regimenwas selected according to the best clinical judgement
of the consultant in charge in Accident and Emergency Room (A & E) at
the time of admission. Upper gastrointestinal bleeding with clinical
relevance was deﬁned as hæmatemesis, gross blood or “coffee grounds”
material in a nasogastric aspirate, or melenæ, complicated by a
spontaneous decrease of more than 20 mm Hg in the systolic blood
pressure, an increase of more than 20 beats per minute in the heart rate,
or a decrease in the hæmoglobin level of more than 2 g/dL [4].
Statistical analysis was performed using SPSS Statistics 17.0, IBM
Company. Quantitative data were expressed as means±standard
deviation (SD).Qualitativedata and their associationwith the treatment
groups were analysed using Pearson Chi-Square Test, considering
P values b0.05 statistically signiﬁcant.
Calculationof the costof prophylaxiswasmadebasedon thenumber
of tablets or intravenous injections of omeprazole administered during
each patient's stay, according to the wholesale price data from the
pharmacy of our hospital.Table 1
Demographic, clinical and laboratory characteristics of the 3 groups of patients.
Characteristics of Patients No prophylaxis O
Age, years (mean±SD) 68±18 70
Gender (M:F), n(%) 80(37):122(38.2) 72
Length of stay, days (mean±SD) 9.0±5.1 10
Cardiovascular disease, n (%) 44(34.1) 50
Cerebrovascular disease, n (%) 40(37.7) 39
Respiratory disease, n (%) 40(35.7) 42
Gastrointestinal disease, n (%) 20(30.3) 27
Other primary diagnosis, n (%) 58(47.5) 35
Infection, n (%) 74(34.3) 68
Neoplasia, n (%) 35(36.1) 32












Anti-platelet therapy, n (%) 101(32.7) 12
NSAIDs, n (%) 21(37.5) 23
Anticoagulation, n (%) 19(35.2) 23
Steroids, n (%) 18(26.5) 28
Legend: n—number of; SD—standard deviation; NSAIDs—nonsteroidal antiinﬂammatory druAll patients gave consent to participate in the study, which was
approved by the local ethics committee.3. Results
Clinical records from 535 patients, 216 (40.4%) men and 319
(59.6%) women, mean age 70±16 (18–98) years, were analysed.
Mean duration of hospitalization was 9.6±7.7 days. Among these,
140 (26.2%) patients were treated with 40 mg of omeprazole
intravenously (i.v.) and daily (qd), 193 (36.1%) were treated with
20 mg of omeprazole orally (p.o.) qd, and 202 (37.8%) patients did not
receive any prophylaxis for stress-related mucosal disease.
There were no differences between the 3 groups of patients
concerning baseline characteristics of patients, disease severity, and
use of NSAIDs, steroids, and anticoagulation (with warfarin or
heparin) at the time of admission (Table 1). All the patients were
able to eat or were fed enterically, and were breathing spontaneously.
When infection was considered there was a difference (p=0.002)
between the group who was treated with i.v. omeprazole and the
other two groups: in the ﬁrst group, the number of patients infected
was signiﬁcantly higher. Concerning Karnofsky score there was also a
difference (p=0.008): the number of totally independent patients
(score I) who received prophylaxis with i.v. omeprazole was
signiﬁcantly lower. There was a higher number of patients treated
with anti-platelet therapy in the group taking oral omeprazole
(p=0.006) (Table 1). None of the patients was treated with any
other stress-related mucosal disease prophylactic agents. There were
no differences in the incidence of nosocomial pneumoniæ in the three
groups and there were no infection by Clostridium difﬁcile.
According to price data provided from the hospital's pharmacy,
each 20 mg tablet of omeprazole costs 0.16 €, versus 6.60 € of the
injectable formulation (40 mg). Considering that patients in the “i.v.
group” were treated with i.v. omeprazole at least half of the time
during their stay in theward (700 days), switching to oral omeprazole
after that and continuing to be on this regimen until discharge, total
cost of prophylaxis reached 5,000,00 €, approximately. This corre-
sponds to an additional spent of 900,00 € per 100 patients admitted to
our ward.
There was one episode (0.2%) of clinically relevant upper
gastrointestinal bleeding in a patient from the group who had no
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In ourpopulation,we found that the incidence of bleeding associated
with stress-related mucosal disease was very low. There was no
difference amongst the treatment groups concerning the baseline
characteristics, and there was no evidence for a beneﬁt in the use of
omeprazole for prophylaxis of clinically relevant bleeding.
In the last two decades, several studies have been trying to deﬁne
factors associated with a high risk for stress-related mucosal disease
bleeding, and whether there is a need for its prophylaxis [10–12]. The
vast majority of these studies have addressed this issue in an ICU-
setting, and by now, despite conﬂicting data, it is consensual that only
patients with respiratory failure requiring prolonged mechanical
ventilation and/or coagulopaphy should receive preventive therapy
[13]. The recognition of the seriousness of the factors that demand
prophylaxis has raised the question of whether this should bemade in
non-ICU patients, whowill naturally lack these clinical syndromes and
therefore will have a lower risk for stress-related mucosal disease
bleeding. Currently, and in real-life practice, prophylaxis continues to
be the standard of care in patients admitted to wards, and PPIs, as the
most effective antisecretory agents, incontestably safe, are undoubt-
edly the universal drug of choice [14].
Only a small number of studies have examined the effectiveness of
this prophylactic attitude in non-ICU patients [9,15], as well as its cost
impact [16,17], and none were proper prospective controlled studies.
These studies have shown a higher incidence of bleeding, but there
were major differences in the populations considered in each one.
Some of those particular characteristics included patients initially
admitted to ICUs [6,15], patients submitted to major surgeries [16,17],
including organ transplant [6], and patients with prolonged times of
admission (more than 14 days) [6]. All these are relevant factors
which are not present in typical medical patients, admitted to internal
medicine wards.
Despite being limited by a non-randomized, open-labelled,
retrospective design, our study was the ﬁrst to focus exclusively on
an internal medicine ward, analysing several different variables
presumably implicated as risk factors for stress-related mucosal
disease bleeding, during an extended period of time (a whole year),
and with one of the largest reported cohorts. Although the decision to
begin prophylaxis relied on a subjective clinical judgement, we found
that most of the baseline characteristics of the patients were
homogeneous among the three groups, whichmade them comparable
between each other. Therewere two exceptions: patients treatedwith
i.v. omeprazole presented a signiﬁcantly higher percentage of infection
and a lower percentage of independency for daily activities; and the
“p.o. group” had a higher percentage of patients treated with anti-
platelet drugs. The former ﬁndingmay be explained by the assumption
of the consultant at admission that more seriously ill patients, fre-
quently infected and dependent, would need prophylaxis and were
unable to swallow a tablet or had an impaired gastrointestinal absorp-
tion. Nevertheless, this difference did not change the outcome of these
patients, (regarding bleeding incidence), signiﬁcantly.
Another issue is whether administration of drugs like NSAIDs, anti-
platelet or anticoagulant agents, or steroids represents an increased
risk for stress-related mucosal disease bleeding. It is widely known
that use of NSAIDs increases the risk of upper gastrointestinal
bleeding 4 to 5-fold, and that this complication has a cumulative
incidence of 0.9–1.4% after 12 months of NSAID exposure [18].
Concerning the other previously referred drugs, prognostic numbersare not so accurate but it is generally accepted that the highest risk lies
on the coexistence of two or more factors like age, prior bleeding
events or association of two of these pharmacological groups [19]. In
our study, most of the patients had co-morbidities and were being
treated with at least one of these drugs. Nevertheless, even if a
signiﬁcant risk exists, the short time of admission lowers the
probability of the occurrence of relevant bleeding.
Finally, extrapolation of costs suggests that prophylaxis of bleeding
might have a signiﬁcant economic impact.
In conclusion, we found that there is no advantage in the use of
omeprazole in preventing stress-related mucosal disease bleeding.
This seems to be mainly due to the low incidence of clinically relevant
bleeding, rather than a lack of efﬁcacy of omeprazole in its
prophylaxis.
5. Learning points
• Patients admitted to an internal medicine ward have a low
incidence of stress-related mucosal disease bleeding.
• There is no advantage in the use of omeprazole for the prevention of
clinically relevant bleeding in this context.
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